710 research outputs found
Probing the isovector transition strength of the low-lying nuclear excitations induced by inverse kinematics proton scattering
A compact approach based on the folding model is suggested for the
determination of the isoscalar and isovector transition strengths of the
low-lying () excitations induced by inelastic proton
scattering measured with exotic beams. Our analysis of the recently measured
inelastic O+p scattering data at and 43 MeV/nucleon
has given for the first time an accurate estimate of the isoscalar
and isovector deformation parameters (which cannot be determined from
the (p,p') data alone by standard methods) for 2 and excited
states in O. Quite strong isovector mixing was found in the 2
inelastic O+p scattering channel, where the strength of the isovector
form factor (prototype of the Lane potential) corresponds to a
value almost 3 times larger than and a ratio of nuclear transition
matrix elements .Comment: 5 pages, 3 figure
Deviation of the Nucleon Shape From Spherical Symmetry: Experimental Status
In this brief pedagogical overview the physical basis of the deviation of the
nucleon shape from spherical symmetry will be presented along with the
experimental methods used to determine it by the gamma* p -> Delta reaction.The
fact that significant non-spherical electric(E2) and Coulomb quadrupole(C2)
amplitudes have been observed will be demonstrated. These multipoles for the
N,Delta system as a function of Q^2 from the photon point through 4 GeV^2 have
been measured with modest precision. Their precise magnitude remains model
dependent due to the contributions of the background amplitudes, although rapid
progress is being made to reduce these uncertainties. A discussion of what is
required to perform a model independent analysis is presented. All of the data
to date are consistent with a prolate shape for the proton (larger at the
poles) and an oblate shape(flatter at the poles) for the Delta. It is suggested
here that the fundamental reason for this lies in the spontaneous breaking of
chiral symmetry in QCD and the resulting, long range(low Q^2), effects of the
pion cloud. This verification of this suggestion, as well as a more accurate
measurement of the deviation from spherical symmetry, requires further
experimental and theoretical effort.Comment: 8 pages, 8 figures, enhanced conference proceeding
Efficient Algorithms for Universal Quantum Simulation
A universal quantum simulator would enable efficient simulation of quantum
dynamics by implementing quantum-simulation algorithms on a quantum computer.
Specifically the quantum simulator would efficiently generate qubit-string
states that closely approximate physical states obtained from a broad class of
dynamical evolutions. I provide an overview of theoretical research into
universal quantum simulators and the strategies for minimizing computational
space and time costs. Applications to simulating many-body quantum simulation
and solving linear equations are discussed
Quasiparticle RPA with finite rank approximation for Skyrme interactions
A finite rank separable approximation for the particle-hole RPA calculations
with Skyrme interactions is extended to take into account the pairing. As an
illustration of the method energies and transition probabilities for the
quadrupole and octupole excitations in some O, Ar, Sn and Pb isotopes are
calculated. The values obtained within our approach are very close to those
that were calculated within QRPA with the full Skyrme interaction. They are in
reasonable agreement with experimental data.Comment: 20 pages, 1 figure, submitted to Phys.Rev.
Considerations on rescattering effects for threshold photo- and electro-production of on deuteron
We show that for the S-state -production in processes and the rescattering effects due to the
transition: (or are cancelled
out due to the Pauli principle. The large values for these effects predicted in
the past may result from the fact that the spin structure of the corresponding
matrix element and the necessary antisymmetrization induced by the presence of
identical protons (or neutrons) in the intermediate state was not taken into
account accurately. One of the important consequences of these considerations
is that photo- and electro-production on deuteron near threshold can
bring direct information about elementary neutron amplitudes.Comment: Add a new sectio
The Oregon Experiment — Effects of Medicaid on Clinical Outcomes
Background: Despite the imminent expansion of Medicaid coverage for low-income adults, the effects of expanding coverage are unclear. The 2008 Medicaid expansion in Oregon based on lottery drawings from a waiting list provided an opportunity to evaluate these effects. Methods: Approximately 2 years after the lottery, we obtained data from 6387 adults who were randomly selected to be able to apply for Medicaid coverage and 5842 adults who were not selected. Measures included blood-pressure, cholesterol, and glycated hemoglobin levels; screening for depression; medication inventories; and self-reported diagnoses, health status, health care utilization, and out-of-pocket spending for such services. We used the random assignment in the lottery to calculate the effect of Medicaid coverage. Results: We found no significant effect of Medicaid coverage on the prevalence or diagnosis of hypertension or high cholesterol levels or on the use of medication for these conditions. Medicaid coverage significantly increased the probability of a diagnosis of diabetes and the use of diabetes medication, but we observed no significant effect on average glycated hemoglobin levels or on the percentage of participants with levels of 6.5% or higher. Medicaid coverage decreased the probability of a positive screening for depression (−9.15 percentage points; 95% confidence interval, −16.70 to −1.60; P=0.02), increased the use of many preventive services, and nearly eliminated catastrophic out-of-pocket medical expenditures. Conclusions: This randomized, controlled study showed that Medicaid coverage generated no significant improvements in measured physical health outcomes in the first 2 years, but it did increase use of health care services, raise rates of diabetes detection and management, lower rates of depression, and reduce financial strain.United States. Dept. of Health and Human Services. Office of the Assistant Secretary for Planning and EvaluationCalifornia HealthCare FoundationNational Institute on Aging (P30AG012810)National Institute on Aging (RC2AGO36631)National Institute on Aging (R01AG0345151)John D. and Catherine T. MacArthur FoundationRobert Wood Johnson FoundationAlfred P. Sloan FoundationSmith Richardson FoundationUnited States. Social Security Administration (5 RRC 08098400-03-00, to the National Bureau of Economic Research as part of the Retirement Research Consortium of the Social Security Administration)Centers for Medicare & Medicaid Services (U.S.
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial
© 2016 AGA Institute Background & Aims Studies are needed to determine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 infections whose prior course of antiviral therapy has failed, and the feasibility of shortening treatment duration. We performed a phase 2 study to determine the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in these patients. Methods We performed a multicenter, open-label trial at 32 sites in the United States and 2 sites in New Zealand from March 3, 2015 to April 27, 2015. Our study included 128 treatment-naïve and treatment-experienced patients (1 with HCV genotype 1b; 33 with HCV genotype 2; 74 with HCV genotype 3; 17 with genotype HCV 4; and 3 with HCV genotype 6), with or without compensated cirrhosis. All patients received sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet) and GS-9857 (100 mg) once daily for 6–12 weeks. The primary end point was sustained virologic response 12 weeks after treatment (SVR12). Results After 6 weeks of treatment, SVR12s were achieved by 88% of treatment-naïve patients without cirrhosis (29 of 33; 95% confidence interval, 72%–97%). After 8 weeks of treatment, SVR12s were achieved by 93% of treatment-naïve patients with cirrhosis (28 of 30; 95% CI, 78%–99%). After 12 weeks of treatment, SVR12s were achieved by all treatment-experienced patients without cirrhosis (36 of 36; 95% CI, 90%–100%) and 97% of treatment-experienced patients with cirrhosis (28 of 29; 95% CI, 82%–100%). The most common adverse events were headache, diarrhea, fatigue, and nausea. Three patients (1%) discontinued treatment due to adverse events. Conclusions In a phase 2 open-label trial, we found sofosbuvir-velpatasvir plus GS-9857 (8 weeks in treatment-naïve patients or 12 weeks in treatment-experienced patients) to be safe and effective for patients with HCV genotype 2, 3, 4, or 6 infections, with or without compensated cirrhosis. ClinicalTrials.gov ID: NCT02378961
Neutral Pion Photoproduction on Nuclei in Baryon Chiral Perturbation Theory
Threshold neutral pion photoproduction on light nuclei is studied in the
framework of baryon chiral perturbation theory. We obtain a general formula for
the electric dipole amplitude in the special case of neutral pion
photoproduction on a nucleus. To third order in small momenta, the amplitude is
a sum of 2- and 3-body interactions with no undetermined parameters. With
reasonable input from the single nucleon sector, our result for neutral pion
photoproduction on the deuteron is in agreement with experiment.Comment: 24 pages, 4 uuencoded postscript figures, uses LaTex and epsf.tex.
Added footnote and references. Minor changes in text and forma
Coherent \pi^0 threshold production from the deuteron at Q^2 = 0.1 GeV^2/c^2
First data on coherent threshold \pi^0 electroproduction from the deuteron
taken by the A1 Collaboration at the Mainz Microtron MAMI are presented. At a
four-momentum transfer of q^2=-0.1 GeV^2/c^2 the full solid angle was covered
up to a center-of-mass energy of 4 MeV above threshold. By means of a
Rosenbluth separation the longitudinal threshold s wave multipole and an upper
limit for the transverse threshold s wave multipole could be extracted and
compared to predictions of Heavy Baryon Chiral Perturbation Theory.Comment: 7 pages, 7 figures, latex2
Chitayat syndrome: hyperphalangism, characteristic facies, hallux valgus and bronchomalacia results from a recurrent c.266A>G p.(Tyr89Cys) variant in the ERF gene.
BACKGROUND: In 1993, Chitayat et al., reported a newborn with hyperphalangism, facial anomalies, and bronchomalacia. We identified three additional families with similar findings. Features include bilateral accessory phalanx resulting in shortened index fingers; hallux valgus; distinctive face; respiratory compromise. OBJECTIVES: To identify the genetic aetiology of Chitayat syndrome and identify a unifying cause for this specific form of hyperphalangism. METHODS: Through ongoing collaboration, we had collected patients with strikingly-similar phenotype. Trio-based exome sequencing was first performed in Patient 2 through Deciphering Developmental Disorders study. Proband-only exome sequencing had previously been independently performed in Patient 4. Following identification of a candidate gene variant in Patient 2, the same variant was subsequently confirmed from exome data in Patient 4. Sanger sequencing was used to validate this variant in Patients 1, 3; confirm paternal inheritance in Patient 5. RESULTS: A recurrent, novel variant NM_006494.2:c.266A>G p.(Tyr89Cys) in ERF was identified in five affected individuals: de novo (patient 1, 2 and 3) and inherited from an affected father (patient 4 and 5). p.Tyr89Cys is an aromatic polar neutral to polar neutral amino acid substitution, at a highly conserved position and lies within the functionally important ETS-domain of the protein. The recurrent ERF c.266A>C p.(Tyr89Cys) variant causes Chitayat syndrome. DISCUSSION: ERF variants have previously been associated with complex craniosynostosis. In contrast, none of the patients with the c.266A>G p.(Tyr89Cys) variant have craniosynostosis. CONCLUSIONS: We report the molecular aetiology of Chitayat syndrome and discuss potential mechanisms for this distinctive phenotype associated with the p.Tyr89Cys substitution in ERF
- …